[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647454":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":28,"collaborators":20,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":20,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":60,"whyStopped":20,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":20},{"fullName":5,"class":6},"MMI (Medical Microinstruments, Inc.)","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Alzheimer's Disease","EXPERIMENTAL","Patient with confirmed mild to moderate Alzheimer's Disease according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria.",[13],"Device: Symani Surgical System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Symani Surgical System","Use of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Clinical Operations","CONTACT","8336646276","5","clinical.ops@mmimicro.com",{"type":29,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100647454","robotic-enabled-microsurgical-intervention-for-neurodegenerative-disease---eu-100647454",false,"NCT07708675","Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EU","Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - A European, Prospective, Multi-Center, Open Label Study in Alzheimer's Patients","REMIND-EU","Preoperative Inclusion Criteria:\n\n1. Patient aged 50 to \\\u003C 80 years\n2. Patient has confirmed highly probable or probable Alzheimer's disease according to the International Working Group (IWG) Patient and has a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria\n3. Patient has an MMSE score≥ 18\n4. Investigator deems the candidate acceptable for lymphatic surgery with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)\n5. Patients who are of childbearing potential must agree to use a medically acceptable form of contraception.\n6. Patient or their legally authorized representative agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure\n\nIntraoperative Inclusion Criteria:\n\n1\\. Intraoperative imaging confirms lymphatic nodes\u002Fvessels amenable to reconstruction\n\nPreoperative Exclusion Criteria:\n\n1. Patient (or their legally authorized representative) is unwilling to provide informed consent\n2. Patient has suspected dementia of other type, e.g., Lewy body, frontotemporal disorder, vascular, etc.\n3. History of head and neck radiation exposure\n4. Patient with severe kidney disease (GFR \\\u003C30 mL\u002Fmin\u002F1.73m2)\n5. Patient with acute kidney injury\n6. Active systemic infection under treatment with intravenous antibiotics\n7. Patient has a modified Rankin Score (mRS) of \\>4\n8. Documented history of clinically significant diagnosis of cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, untreated sleep apnea, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion\n9. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n10. Patient with an active cancer diagnosis and\u002For currently receiving treatment for cancer or has received treatment within the past 6 months\n11. Patient is currently receiving treatment or has been treated with anti-amyloid-beta monoclonal antibody therapy within the past 6 months\n12. Patient has contraindication for MRI\n13. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or study outcomes\n14. Patient is ineligible to participate for other reasons in the judgment of the investigator\n\nIntraoperative Exclusion Criteria:\n\n1\\. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest","ALL","50 Years","80 Years",{"count":42,"type":43},50,"ESTIMATED","INTERVENTIONAL",[46],"NA","The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease.",[49],"Alzheimer's",[51,52,53,54,55,56,57,58,59],"Dementia","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Tauopathies","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorders","Alzheimer Disease","NOT_YET_RECRUITING","2026-07-15",{"date":63,"type":64},"2026-07-16","ACTUAL",{"date":66,"type":43},"2026-10-01",{"date":68,"type":43},"2029-03-01",{"name":5,"class":6}]